Medicure Inc

Our ProductsAGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)TARDOXALTM - in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet needAbout MedicureMedicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics.HistoryMedicure founded in 1997 is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. Medicure has raised over $140 million and focused this investment on the advancement and clinical development of cardiovascular drugs. In 2006 Medicure acquired the USA commercial rights to AGGRASTAT (tirofiban HCl), a cardiovascular drug originally developed by Merck. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome. Medicurés business is generating revenue to support operations and to make selected investments in the clinical advancement of AGGRASTAT.TodayMedicurés core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT.